Cadrenal Therapeutics (NASDAQ:CVKD) Releases Earnings Results, Misses Expectations By $1.03 EPS

Cadrenal Therapeutics (NASDAQ:CVKD) posted its earnings results on Thursday. The company reported ($2.74) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.71) by ($1.03), Zacks reports.

Cadrenal Therapeutics Stock Performance

CVKD stock opened at $19.09 on Friday. Cadrenal Therapeutics has a 1 year low of $5.40 and a 1 year high of $22.90. The firm has a market cap of $34.04 million, a P/E ratio of -2.86 and a beta of 1.40. The stock has a 50-day simple moving average of $18.31 and a 200-day simple moving average of $15.03.

About Cadrenal Therapeutics

Cadrenal Therapeutics, Inc operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel oral and reversible anticoagulant to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, atrial fibrillation, and thrombotic anti-phospholipid syndrome.